Placing Arcadia Biosciences, Inc. (NasdaqCM:RKDA) shares under the microscope we note that the firm has a current Return on Equity of -1.222257. Simply put, this ratio determines how well the firm uses investment funds to generate profit. This ratio is often considered “the mother of all ratios” as it often reveals how well a company is operating.

Individual investors may be going to great lengths to make their hard earned money work for them in the stock market. The stock market can be a scary place for beginners with little to no experience. Studying the ins and outs of the markets can help provide a solid base for the new investor to work with. Many people will jump into the game thinking they are going to easily make large profits in the market. Although this is a possibility, many investors will learn the hard way that sustaining profits over the long-term can be a tough endeavor. Studying all the different company information can take up a lot of time and energy. Some people just don’t have the time they would like to put into stock market study.

In addition to ROE, investors might also take into consideration some other ratios. One of the most popular ratios is the “Return on Assets” (aka ROA). This score indicates how profitable a company is relative to its total assets. The Return on Assets for Arcadia Biosciences, Inc. (NasdaqCM:RKDA) is -0.832227. This number is calculated by dividing net income after tax by the company’s total assets. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The Return on Invested Capital (aka ROIC) for Arcadia Biosciences, Inc. (NasdaqCM:RKDA) is -4.249795. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Arcadia Biosciences, Inc. (NasdaqCM:RKDA) is -0.429529. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Arcadia Biosciences, Inc. (NasdaqCM:RKDA) is -1.015772.

After a recent scan, we can see that Arcadia Biosciences, Inc. (NasdaqCM:RKDA) has a Shareholder Yield of -1.238162 and a Shareholder Yield (Mebane Faber) of -1.23739. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

**Quant Scores**

Checking in on some valuation rankings, Arcadia Biosciences, Inc. (NasdaqCM:RKDA) has a Value Composite score of 85. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 90.

Investors may be interested in viewing the Gross Margin score on shares of Arcadia Biosciences, Inc. (NasdaqCM:RKDA). The name currently has a score of 50.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

Active investors are constantly weighing risk and return when trading in the stock market. Every investor has to evaluate their risk appetite at some point. The amount of risk an investor is willing to take on can have a large impact on expected future returns. Some people may be much more comfortable with riskier investments than others. This can greatly vary from one person to the next. Once the individual investor is comfortable with the amount of money on the table, they should be able to spend their energies focused on finding a winning strategy. Finding a winning strategy may involve many different aspects of stock research. Following a plan may help investors plow through downturns in the markets, and being able to change the plan when things aren’t working can also be a help to longer-term portfolio health.

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) has a current MF Rank of 19540. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) has a current ERP5 Rank of 16872. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Investors are constantly striving to get on top in the stock market. Everyone wants to find that next winner to jumpstart the portfolio. Investors often identify risk preference when trying to sort out asset allocation. Typically, a greater amount of risk may provide a greater chance for growth. Many investors may struggle with the concept of keeping emotion out of choosing stocks. Equity research often requires a high degree of patience, dedication, and practice. Learning everything possible about the markets can help the individual build a good base to work with. Being able to sort out the data to determine what is relevant information can help with those tough investment decisions.

**Price Index & Volatility**

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Arcadia Biosciences, Inc. (NasdaqCM:RKDA) is 193.390200. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Arcadia Biosciences, Inc. (NasdaqCM:RKDA) is 68.921800. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 68.072800.

We can now take a quick look at some historical stock price index data. Arcadia Biosciences, Inc. (NasdaqCM:RKDA) presently has a 10 month price index of 0.81534. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.83617, the 24 month is 0.16795, and the 36 month is 0.04975. Narrowing in a bit closer, the 5 month price index is 0.48941, the 3 month is 0.64216, and the 1 month is currently 0.91395.

Making smart choices when picking stocks is typically a top priority for successful investors. For new investors with little market knowledge, this can be challenging. Figuring out how to start building the stock portfolio may take a lot of time and effort. When the individual investor decides that they want to manage their own portfolio and make their own trades, the journey has just begun. Many individuals will be tempted to pursue stock trading plans based on advice from friends, colleagues, or family members. Even though certain plans may work for someone else, there is no guarantee that success will transfer to others. Investors often need to do their own research in order to obtain as much knowledge as possible before diving in to the markets.

**Receive News & Ratings Via Email** - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.